Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin—an electronic health-record-based study

Current Medical Research and Opinion

Volumn 32, Issue 6, 2016, Pages 1151-1159

  Lefebvre, Patrick ^a   Pilon, Dominic ^a   Robitaille, Marie Noëlle ^a   Lafeuille, Marie Hélène ^a   Chow, Wing ^b   Pfeifer, Michael ^b   Duh, Mei Sheng ^c  

^a GROUPE D ANALYSE   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

Blood pressure; canagliflozin; HbA1c; type 2 diabetes mellitus; weight

Indexed keywords

BIGUANIDE DERIVATIVE; CANAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; ELECTRONIC HEALTH RECORD; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; WEIGHT CONTROL; WEIGHT REDUCTION; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FACTUAL DATABASE; GLUCOSE BLOOD LEVEL; PATHOPHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84966698670     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1183604     Document Type: Article

References (27)

1. American Diabetes Association. Standards of medical care in diabetes - 2014. Diabetes Care 2014;37:S14-80
2. Y.Handelsman, Z.T.Bloomgarden, G.Grunberger,. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) – Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015. Endocr Pract 2015;21(Suppl 1):1-87
3. A.J.Palmer, S.Roze, W.J.Valentine,. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin 2004;20(Suppl 1):S53-8
4. American Diabetes Association. Standards of Medical Care in diabetes. Diabetes Care 2015;38(Suppl 1):S1-94
5. National Committee for Quality Assurance. HEDIS Measures. HEDIS 2015. The publisher is National Committee for Quality Assurance, 2015. http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures.aspx
6. S.Stark Casagrande, J.E.Fradkin, S.H.Saydah,. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013;36:2271-9
7. R.BaileyRa, U.Vijapurkar, G.Meininger,. Diabetes-related composite quality end point attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Clin Ther 2015;37:1045-54
8. D.M.Battise Efficacy and safety of canagliflozin as add-on therapy to metformin in type 2 diabetes. Clin Diabetes 2014;32:81-6
9. K.Stenlöf, W.T.Cefalu, K.Kim,. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
10. F.J.Lavalle-González, A.Januszewicz, J.Davidson,. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
11. T.Forst, R.Guthrie, R.Goldenberg,. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16:467-77
12. G.Schernthaner, J.L.Gross, J.Rosenstock,. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-15
13. W.T.Cefalu, L.LeiterLa, K.H.Yoon,. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
14. Q.Meng, Y.Shen, D.Liu,. Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials. J Diabetes Investig 2016;7:359-65
15. L.Meckley, G.Miyasato, F.Kokkotos,. An observational study of glycemic control in canagliflozin treated patients. Curr Med Res Opin 2015;31:1479-86
16. A.Nardolillo, M.Kane, R.Busch,. A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes 2014;7:25-30
17. E.K.Buysman, W.Chow, H.J.Henk,. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin 2015;31:137-43
18. United States Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes. FDA News Release, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm
19. M.E.Charlson, P.Pompei, K.L.Ales,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
20. B.A.Young, E.Lin, M.Von Korff,. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-23
21. Elixhauser A, Steiner C, Kruzikas. D. Comorbidity Software Documentation. 2004. HCUP Methods Series Report # 2004-1. ONLINE February 6, 2004. U.S. Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/reports/ComorbiditySoftwareDocumentationFinal.pdf. Accessed April 25, 2016.
22. R.A.Bailey, U.Vijapurkar, G.E.Meininger,. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Am J Manag Care 2014;20(Suppl 13):s296-305
23. R.A.Bailey, C.V.Damaraju, S.C.Martin,. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. Am J Manag Care 2014;20(Suppl 1):s16-24
24. L.Blonde, V.Woo, C.Mathieu,. Achievement of diabetes-related treatment goals with canagliflozin in patients with type 2 diabetes mellitus. San Francisco, CA: American Diabetes Association (ADA); 2014
25. B.Bode, K.Stenlöf, S.Harris,. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015;17:294-303
26. L.LeiterLa, K.-H.Yoon, P.Arias,. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355-64
27. Janssen Pharmaceuticals Inc. Prescribing information for Invokana® (canagliflozin), tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2016